Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 6 of 6 results for modafinil

  1. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

    NICE guideline
    Published
    22 June 2022
    View recommendations

    Sections for NG220

  2. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.

    Technology appraisal guidance
    Published
    5 January 2022
    View recommendations

    Sections for TA758

  3. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

    NICE guideline
    Published
    19 July 2017
    View recommendations

    Sections for NG71

  4. Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

    Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

    Evidence summary
    Published
    14 March 2017

  5. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

    Evidence summary
    Published
    2 April 2013

  6. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    29 September 2015